STOCK TITAN

Syndax Announces Participation in September Investor Conferences

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two upcoming investor conferences in September 2025.

CEO Michael A. Metzger and the management team will present at Citi's 2025 BioPharma Back to School Conference on September 2 at 4:45 p.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website.

Loading...
Loading translation...
Argus Aug 26 session
+1.21% close to close 1.2x rel. volume Open Argus
Details

News Market Reaction – SNDX

On Aug 26, the day this news came out, SNDX closed 1.21% above the previous close.

Data tracked by StockTitan Argus for the Aug 26 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • Citi’s 2025 BioPharma Back to School Conference with a fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET.
  • H.C. Wainwright 27th Annual Global Investment Conference with a company presentation on Monday, September 8, 2025, at 9:00 a.m. ET.

A live webcast of these sessions will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Syndax (SNDX) presenting at the Citi BioPharma Conference 2025?

Syndax will present at Citi's BioPharma Conference on Tuesday, September 2, 2025, at 4:45 p.m. ET in a fireside chat format.

Who will represent Syndax Pharmaceuticals at the September 2025 investor conferences?

CEO Michael A. Metzger and members of the Syndax management team will represent the company at the conferences.

How can investors access Syndax's (SNDX) conference presentations?

Investors can access the live webcasts and replays of the presentations through the Investor section of Syndax's website at www.syndax.com.

What time is Syndax's presentation at the H.C. Wainwright Conference?

Syndax will give a company presentation at the H.C. Wainwright Conference on Monday, September 8, 2025, at 9:00 a.m. ET.

Keep reading